TY - JOUR
T1 - Association of Torquetenovirus Viremia with Physical Frailty and Cognitive Impairment in Three Independent European Cohorts
AU - Giacconi, Robertina
AU - Laffon, Blanca
AU - Costa, Solange
AU - Teixeira-Gomes, Armanda
AU - Maggi, Fabrizio
AU - MacEra, Lisa
AU - Spezia, Pietro Giorgio
AU - Piacenza, Francesco
AU - Bürkle, Alexander
AU - Moreno-Villanueva, María
AU - Bonassi, Stefano
AU - Valdiglesias, Vanessa
AU - Teixeira, Joao Paulo
AU - Dollé, Martijn E.T.
AU - Rietman, M. Liset
AU - Jansen, Eugène
AU - Grune, Tilman
AU - Gonos, Efstathios S.
AU - Franceschi, Claudio
AU - Capri, Miriam
AU - Weinberger, Birgit
AU - Sikora, Ewa
AU - Stuetz, Wolfgang
AU - Toussaint, Olivier
AU - Debacq-Chainiaux, Florence
AU - Hervonen, Antti
AU - Hurme, Mikko
AU - Slagboom, P. Eline
AU - Schön, Christiane
AU - Bernhardt, Jürgen
AU - Breusing, Nicolle
AU - Pásaro, Eduardo
AU - Maseda, Ana
AU - Lorenzo-López, Laura
AU - Millán-Calenti, José Carlos
AU - Provinciali, Mauro
AU - Malavolta, Marco
N1 - Publisher Copyright:
© 2023 Authors. All rights reserved.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Introduction: Immunosenescence and inflammaging have been implicated in the pathophysiology of frailty. Torquetenovirus (TTV), a single-stranded DNA anellovirus, the major component of the human blood virome, shows an increased replication rate with advancing age. An elevated TTV viremia has been associated with an impaired immune function and an increased risk of mortality in the older population. The objective of this study was to analyze the relation between TTV viremia, physical frailty, and cognitive impairment. Methods: TTV viremia was measured in 1,131 nonfrail, 45 physically frail, and 113 cognitively impaired older adults recruited in the MARK-AGE study (overall mean age 64.7 ± 5.9 years), and then the results were checked in two other independent cohorts from Spain and Portugal, including 126 frail, 252 prefrail, and 141 nonfrail individuals (overall mean age: 77.5 ± 8.3 years). Results: TTV viremia ≥4log was associated with physical frailty (OR: 4.69; 95% CI: 2.06-10.67, p < 0.0001) and cognitive impairment (OR: 3.49, 95% CI: 2.14-5.69, p < 0.0001) in the MARK-AGE population. The association between TTV DNA load and frailty status was confirmed in the Spanish cohort, while a slight association with cognitive impairment was observed (OR: 1.33; 95% CI: 1.000-1.773), only in the unadjusted model. No association between TTV load and frailty or cognitive impairment was found in the Portuguese sample, although a negative association between TTV viremia and MMSE score was observed in Spanish and Portuguese females. Conclusions: These findings demonstrate an association between TTV viremia and physical frailty, while the association with cognitive impairment was observed only in the younger population from the MARK-AGE study. Further research is necessary to clarify TTV's clinical relevance in the onset and progression of frailty and cognitive decline in older individuals.
AB - Introduction: Immunosenescence and inflammaging have been implicated in the pathophysiology of frailty. Torquetenovirus (TTV), a single-stranded DNA anellovirus, the major component of the human blood virome, shows an increased replication rate with advancing age. An elevated TTV viremia has been associated with an impaired immune function and an increased risk of mortality in the older population. The objective of this study was to analyze the relation between TTV viremia, physical frailty, and cognitive impairment. Methods: TTV viremia was measured in 1,131 nonfrail, 45 physically frail, and 113 cognitively impaired older adults recruited in the MARK-AGE study (overall mean age 64.7 ± 5.9 years), and then the results were checked in two other independent cohorts from Spain and Portugal, including 126 frail, 252 prefrail, and 141 nonfrail individuals (overall mean age: 77.5 ± 8.3 years). Results: TTV viremia ≥4log was associated with physical frailty (OR: 4.69; 95% CI: 2.06-10.67, p < 0.0001) and cognitive impairment (OR: 3.49, 95% CI: 2.14-5.69, p < 0.0001) in the MARK-AGE population. The association between TTV DNA load and frailty status was confirmed in the Spanish cohort, while a slight association with cognitive impairment was observed (OR: 1.33; 95% CI: 1.000-1.773), only in the unadjusted model. No association between TTV load and frailty or cognitive impairment was found in the Portuguese sample, although a negative association between TTV viremia and MMSE score was observed in Spanish and Portuguese females. Conclusions: These findings demonstrate an association between TTV viremia and physical frailty, while the association with cognitive impairment was observed only in the younger population from the MARK-AGE study. Further research is necessary to clarify TTV's clinical relevance in the onset and progression of frailty and cognitive decline in older individuals.
KW - Aging
KW - Cognitive impairment
KW - Inflammation
KW - Physical frailty
KW - Torquetenovirus
UR - http://www.scopus.com/inward/record.url?scp=85163220706&partnerID=8YFLogxK
U2 - 10.1159/000528169
DO - 10.1159/000528169
M3 - Article
C2 - 36538907
AN - SCOPUS:85163220706
SN - 0304-324X
VL - 69
SP - 684
EP - 693
JO - Gerontology
JF - Gerontology
IS - 6
ER -